Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reply
- PMID: 38483395
- DOI: 10.1001/jamaoncol.2024.0119
Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reply
Comment on
-
Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma.JAMA Oncol. 2024 May 1;10(5):674. doi: 10.1001/jamaoncol.2024.0116. JAMA Oncol. 2024. PMID: 38483380 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical